The limited experimental evidence available shows that, in cancer cells, a cross-regulation between FASN and HER2 exists [3,5], and also that pharmacological blockade of FASN with C75 can overcome acquired resistance to trastuzumab [38]. This evidence concerns the gene FASN and cancer.